Veterinary Infectious Disease Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Veterinary Infectious Disease Therapeutics Market Analysis
Microorganisms are tiny living creatures that are present everywhere, such as bacteria and viruses. Few of the thousands of species of microorganisms invade, multiply, and cause illness in animals and people. Most of the microorganisms live on the skin, in the mouth, upper airways and intestines without causing any harmful disease but some of the microorganism lives in or on a pet, or invades and causes disease depends on the nature of the microorganism and the state of the pet's natural defenses.
According to World Small Animal Veterinary Association (WSAVA), estimates that 60% to 80% of emerging diseases are zoonotic which indicates the importance of veterinarians in the identification, prevention, and control of infectious diseases. For Example, Rift Valley Fever is an endemic zoonotic disease in Africa and the Middle East that costs producers USD 427 million every year. Increasing prevalence of infectious disease and increasing demand for dairy, meat, and poultry products due to the increasing population size are the key driving factors in the veterinary infectious disease therapeutics market.
Veterinary Infectious Disease Therapeutics Market Trends
This section covers the major market trends shaping the Veterinary Infectious Disease Therapeutics Market according to our research experts:
Antibiotics Segment is Expected to Hold a Major Market Share in the Veterinary Infectious Disease Therapeutics Market
Antibiotic drugs are generally used in veterinary medicine to treat infectious diseases that are caused by bacteria and other microorganisms. Different classes of antibiotics are available for the treatment of infectious diseases in animals, including penicillins, cephalosporins, cephamycins, aminoglycosides, etc. Zoonotic diseases are infectious diseases caused by infections, organisms, and parasites that spread between animals and humans. According to the Centers for Disease Control and Prevention, in the year 2017, found that 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths are caused due to zoonotic diseases.
Hence, owing to the rising number of zoonotic diseases, along with rising pet ownership and increasing research and development (R&D) activities in the veterinary therapeutics are expected to drive the market growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America expected to hold a major market share in the global veterinary infectious disease therapeutics market due to the rising prevalence of veterinary infectious disease, rising companion animal healthcare expenditure in this region. As per the American Heartworm Society, the number of dogs diagnosed with heartworm per clinic has risen by 21 percent in the United States and its territories between 2013 and 2016. Moreover, increasing the adoption of veterinary products and advancements in veterinary infectious disease therapeutics technology is fueling the growth of the overall regional market to a large extent.
Veterinary Infectious Disease Therapeutics Industry Overview
The veterinary infectious disease therapeutics market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the major market players are Elanco, Merck & Co. Inc, Boehringer Ingelheim Vetmedica, Zoetis, Dechra Pharmaceuticals PLC, Ceva Sante, Virbac S.A, Bayer AG, Vetoquinol S.A, IDEXX Laboratories, Inc.
Veterinary Infectious Disease Therapeutics Market Leaders
-
Elanco
-
Merck & Co. Inc
-
Boehringer Ingelheim Vetmedica
-
Zoetis
-
Dechra Pharmaceuticals PLC
*Disclaimer: Major Players sorted in no particular order
Veterinary Infectious Disease Therapeutics Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Prevalence of Infectious Diseases in Animals
-
4.2.2 Technological Advancements in Development of New Drugs
-
-
4.3 Market Restraints
-
4.3.1 Stringent Government Regulations
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Product Type
-
5.1.1 Antibiotics
-
5.1.2 Antiviral
-
5.1.3 Antifungal
-
5.1.4 Amebicides
-
5.1.5 Others
-
-
5.2 By Animal Type
-
5.2.1 Dogs and Cats
-
5.2.2 Horses
-
5.2.3 Swine
-
5.2.4 Poultry
-
5.2.5 Other Animals
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Elanco
-
6.1.2 Merck & Co. Inc
-
6.1.3 Boehringer Ingelheim Vetmedica, Inc.
-
6.1.4 Zoetis Inc.
-
6.1.5 Dechra Pharmaceuticals PLC
-
6.1.6 Ceva Santé Animale
-
6.1.7 Virbac S.A
-
6.1.8 Bayer AG
-
6.1.9 Vetoquinol S.A
-
6.1.10 IDEXX Laboratories, Inc.
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Veterinary Infectious Disease Therapeutics Industry Segmentation
As per the scope of the report, veterinary infectious diseases are the diseases that can get transmitted from one animal to another animal or into a human being. Despite their overwhelming abundance, relatively few of the hundreds of thousands of species of microorganisms invade, multiply, and cause illness in animals and people.
| By Product Type | |
| Antibiotics | |
| Antiviral | |
| Antifungal | |
| Amebicides | |
| Others |
| By Animal Type | |
| Dogs and Cats | |
| Horses | |
| Swine | |
| Poultry | |
| Other Animals |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Veterinary Infectious Disease Therapeutics Market Research FAQs
What is the current Veterinary Infectious Disease Therapeutics Market size?
The Veterinary Infectious Disease Therapeutics Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in Veterinary Infectious Disease Therapeutics Market?
Elanco, Merck & Co. Inc, Boehringer Ingelheim Vetmedica, Zoetis and Dechra Pharmaceuticals PLC are the major companies operating in the Veterinary Infectious Disease Therapeutics Market.
Which is the fastest growing region in Veterinary Infectious Disease Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Veterinary Infectious Disease Therapeutics Market?
In 2024, the North America accounts for the largest market share in Veterinary Infectious Disease Therapeutics Market.
What years does this Veterinary Infectious Disease Therapeutics Market cover?
The report covers the Veterinary Infectious Disease Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Veterinary Infectious Disease Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Veterinary Infectious Disease Therapeutics Industry Report
Statistics for the 2024 Veterinary Infectious Disease Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Veterinary Infectious Disease Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
